Table 4.
Logistic regression analysis of the factors associated with hospitalisation in patients with rheumatic disease and COVID-19
| Variables | P value | OR (95% CI) |
| Treatment of the rheumatic disease | ||
| Treatment (csDMARDs) | ||
| ts/bDMARDs | 0.153 | 0.549 (0.242 to 1.249) |
| bDMARDs | ||
| TNF inhibitors | 0.018 | 0.320 (0.125 to 0.821) |
| IL-17-inhibitors | 0.399 | 0.472 (0.082 to 2.701) |
| Anti-CD20 | 0.073 | 4.849 (0.863 to 27.249) |
| Anti-BAFF | 0.796 | 0.529 (0.004 to 66.128) |
| IL-6 inhibitors | 0.294 | 0.400 (0.072 to 2.217) |
| Others | 0.679 | 0.741 (0.180 to 3.057) |
| tsDMARDs | 0.830 | 0.869 (0.241 to 3.130) |
| Glucocorticoids (no) | 0.164 | 1.692 (0.807 to 3.546) |
| Demographics | ||
| Age | <0.001 | 1.053 (1.024 to 1.082) |
| Sex (female) | 0.043 | 2.310 (1.025 to 5.207) |
| Comorbidities | ||
| COPD (no) | 0.054 | 6.639 (0.968 to 45.542) |
| Overweight/obesity (no) | 0.039 | 2.222 (1.043 to 4.733) |
| Chronic liver disease (no) | 0.045 | 5.003 (1.036 to 24.161) |
| COVID-19 symptoms | ||
| Fever (no) | <0.001 | 6.093 (2.673 to 13.887) |
| Cough (no) | 0.089 | 1.896 (0.908 to 3.959) |
| Sore throat (no) | 0.003 | 0.210 (0.074 to 0.595) |
| Dyspnoea (no) | <0.001 | 11.515 (5.453 to 24.316) |
| Arthralgia (no) | 0.001 | 0.183 (0.068 to 0.497) |
| Nausea (no) | 0.002 | 4.379 (1.708 to 11.225) |
| Asthaenia (no) | 0.028 | 2.263 (1.092 to 4.687) |
| Disease-related factors | ||
| Diagnosis (RA) | ||
| Spondyloarthropathies | 0.508 | 0.719 (0.270 to 1.912) |
| Systemic lupus erythematosus | 0.176 | 0.401 (0.107 to 1.509) |
| Other rheumatic diseases | 0.257 | 0.465 (0.124 to 1.744) |
bDMARD, biological disease-modifying antirheumatic drugs; COPD, chronic obstructive pulmonary disease; csDMARD, conventional synthetic disease-modifying antirheumatic drugs; ICU, intensive care unit; IL, interleukin; RA, rheumatoid arthritis; TNF, tumour necrosis factor; tsDMARD, targeted synthetic disease-modifying antirheumatic drugs.